Meinian Onehealth and Astra Biotechnology Partner on Hypersensitive Blood Biomarker Detection
China-based Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a partnership with...
Immorna Enrolls First Patient in Phase I Study of JCXH-211 for Malignant Tumors
Immorna (Hangzhou) Biotechnology, an mRNA-based vaccine developer based in Hangzhou, has announced the enrollment of...
CDE Issues Guidelines on Single-Arm Clinical Trials for Antitumor Drugs
The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for the Applicability of...
XtalPi and DP Technology Partner to Accelerate Pre-Clinical Drug Development with AI
Sino-US artificial intelligence (AI) firm XtalPi Inc. has entered into a partnership with Beijing-based DP...
Laekna Therapeutics Files for IPO on Hong Kong Stock Exchange, Aims to Expand Cancer and Hepatic Fibrosis Therapies
China’s Laekna Therapeutics Shanghai Co., Ltd has filed for an initial public offering (IPO) with...
LanssonPharm’s Anti-Depression Drug LS21031 Receives CDE Approval for Clinical Trials
China-based central nervous system (CNS) drug developer LanssonPharm has announced that it has received clinical...
GSK’s Nucala Gains NMPA Approval for Severe Eosinophilic Asthma in China
UK-based GSK plc (NYSE: GSK) has announced that a market approval filing for Nucala (mepolizumab)...
Juventas Cell Therapy’s CNCT19 Receives FDA IND Approval for r/r B-ALL Treatment
China-based Juventas Cell Therapy Ltd’s chimeric antigen receptor (CAR) T-cell therapy, CNCT19 (Inaticabtagene Autoleucel), has...
Bio-Thera Solutions Initiates First Patient Dosing in Phase I Study of BAT8007
China-based Bio-Thera Solutions, Ltd. (SHA: 688177) has announced the first patient dosing in a multi-center,...
Antengene to Begin Phase I Clinical Study of ATG-022 for Advanced Solid Tumors
China-based Antengene Corporation Ltd (HKG: 6996) is poised to commence a Phase I clinical study...
Guangdong Zhongsheng’s RAY1225 Receives NMPA Approval for Clinical Study
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that it has received approval...
AnnJi Pharma Signs USD 250 Million Licensing Deal with Avenue Therapeutics for Kennedy’s Disease Drug
Taiwan-based AnnJi Pharmaceutical Co., Ltd has announced the signing of a licensing agreement with US...
Vcanbio’s VUM02 Gains CDE Review for Liver Failure and ARDS Clinical Trials
Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that two additional clinical...
Luye Pharma’s Biosimilar BA9101 Completes Phase III Study Enrollment with Ocumension
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd, has completed...
Immunophage Biotech Raises RMB 200 Million in Series B1 Financing for Clinical Trials
Nanjing-based Immunophage Biotech Co., Ltd reportedly raised close to RMB 200 million (USD 29.1 million)...
Akeso Biopharma Enrolls First Subject in Phase III Study of Cadonilimab for Gastric Cancer
China-based Akeso Biopharma (HKG: 9926) has announced the enrollment of the first subject in a...
CSPC Pharmaceutical’s PD-1 Monoclonal Antibody Enlangsubai Completes NMPA Market Approval Filing
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the completion of a market approval...
Pasteur Institute Suspends Joint Venture with Chinese Academy of Sciences
France’s Pasteur Institute has announced its decision to suspend its joint-venture (JV) partnership with the...
Boston Scientific Launches REPLACE Study for FARAPULSE PFA System in China
US-based medical technology major Boston Scientific Corporation (NYSE: BSX) has announced the initiation of the...
Chipscreen’s Epidaza Receives TFDA Approval for Breast Cancer Treatment in Taiwan
Shenzhen Chipscreen Pharmaceutical Co., Ltd’s partner, GNT Biotech & Medicals Corporation, has announced that it...